Johnson & Johnson (JNJ)vsLumexa Imaging Holdings, Inc. Common Stock (LMRI)
JNJ
Johnson & Johnson
$261.44
+1.93%
HEALTHCARE · Cap: $613.99B
LMRI
Lumexa Imaging Holdings, Inc. Common Stock
$10.54
+2.03%
HEALTHCARE · Cap: $974.68M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 9286% more annual revenue ($97.93B vs $1.04B). JNJ leads profitability with a 21.5% profit margin vs -2.7%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
LMRI
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-82.7%
Fair Value
$141.39
Current Price
$261.44
$120.05 premium
Intrinsic value data unavailable for LMRI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 3.2%
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : LMRI
The strongest argument for LMRI centers on Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : LMRI
The primary concerns for LMRI are EPS Growth, Market Cap, Operating Margin. Debt-to-equity of 1.59 is elevated, increasing financial risk.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LMRI is a turnaround play — different risk/reward profiles.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 38/100), backed by strong 21.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Lumexa Imaging Holdings, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?